• First hyperdiploidy event occurred within the first 3 decades of life and took a decade to complete.

  • An MM cell accumulated 0.56 mutations per megabase before HMM, and for every clonal pre-HMM mutation, 1.21 mutations accumulated after HMM.

Abstract

Nearly half of patients with multiple myeloma (MM) have hyperdiploidy (HMM) at diagnosis. Although HMM occurs early, the mutational processes before and after hyperdiploidy are still unclear. Here, we used 72 whole-genome sequencing samples from patients with HMM and identified pre- and post-HMM mutations to define the chronology of the development of hyperdiploidy. An MM cell accumulated a median of 0.56 mutations per megabase before HMM, and for every clonal pre-HMM mutation, 1.21 mutations per megabase accumulated after HMM. This analysis using mutations before and after hyperdiploidy shows that hyperdiploidy happens after somatic hypermutation. Prehyperdiploidy mutations are activation-induced cytidine deaminase and age/clock-like signature driven, whereas posthyperdiploidy mutations are from DNA damage and APOBEC. Interestingly, the first hyperdiploidy event occurred within the first 3 decades of life and took a decade to complete. Copy number changes affecting chromosomes 15 and 19 occurred first. Finally, mutations before initiating event affected chromosomes at different rates, whereas post–initiating event mutational processes affect each chromosome equally.

1.
Avet-Loiseau
H
,
Li
C
,
Magrangeas
F
, et al
.
Prognostic significance of copy-number alterations in multiple myeloma
.
J Clin Oncol
.
2009
;
27
(
27
):
4585
-
4590
.
2.
Chesi
M
,
Bergsagel
PL
.
Molecular pathogenesis of multiple myeloma: basic and clinical updates
.
Int J Hematol
.
2013
;
97
(
3
):
313
-
323
.
3.
Kumar
SK
,
Rajkumar
V
,
Kyle
RA
, et al
.
Multiple myeloma
.
Nat Rev Dis Primers
.
2017
;
3
:
17046
.
4.
Robiou du Pont
S
,
Cleynen
A
,
Fontan
C
, et al
.
Genomics of multiple myeloma
.
J Clin Oncol
.
2017
;
35
(
9
):
963
-
967
.
5.
Samur
MK
,
Aktas Samur
A
,
Fulciniti
M
, et al
.
Genome-wide somatic alterations in multiple myeloma reveal a superior outcome group
.
J Clin Oncol
.
2020
;
38
(
27
):
3107
-
3118
.
6.
Walker
BA
,
Mavrommatis
K
,
Wardell
CP
, et al
.
Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma
.
Blood
.
2018
;
132
(
6
):
587
-
597
.
7.
Aktas Samur
A
,
Minvielle
S
,
Shammas
M
, et al
.
Deciphering the chronology of copy number alterations in multiple myeloma
.
Blood Cancer J
.
2019
;
9
(
4
):
39
.
8.
Bolli
N
,
Maura
F
,
Minvielle
S
, et al
.
Genomic patterns of progression in smoldering multiple myeloma
.
Nat Commun
.
2018
;
9
(
1
):
3363
.
9.
Samur
MK
,
Shah
PK
,
Wang
X
, et al
.
The shaping and functional consequences of the dosage effect landscape in multiple myeloma
.
BMC Genomics
.
2013
;
14
:
672
.
10.
Barwick
BG
,
Gupta
VA
,
Vertino
PM
,
Boise
LH
.
Cell of origin and genetic alterations in the pathogenesis of multiple myeloma
.
Front Immunol
.
2019
;
10
:
1121
.
11.
Barwick
BG
,
Neri
P
,
Bahlis
NJ
, et al
.
Multiple myeloma immunoglobulin lambda translocations portend poor prognosis
.
Nat Commun
.
2019
;
10
(
1
):
1911
.
12.
Manier
S
,
Salem
KZ
,
Park
J
,
Landau
DA
,
Getz
G
,
Ghobrial
IM
.
Genomic complexity of multiple myeloma and its clinical implications
.
Nat Rev Clin Oncol
.
2017
;
14
(
2
):
100
-
113
.
13.
Kumar
SK
,
Rajkumar
SV
.
The multiple myelomas - current concepts in cytogenetic classification and therapy
.
Nat Rev Clin Oncol
.
2018
;
15
(
7
):
409
-
421
.
14.
Maura
F
,
Bolli
N
,
Angelopoulos
N
, et al
.
Genomic landscape and chronological reconstruction of driver events in multiple myeloma
.
Nat Commun
.
2019
;
10
(
1
):
3835
.
15.
Cirrincione
AM
,
Poos
AM
,
Ziccheddu
B
, et al
.
The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma
.
Blood
.
2024
;
144
(
7
):
771
-
783
.
16.
Rustad
EH
,
Yellapantula
V
,
Leongamornlert
D
, et al
.
Timing the initiation of multiple myeloma
.
Nat Commun
.
2020
;
11
(
1
):
1917
.
17.
Maura
F
,
Landgren
O
,
Morgan
GJ
.
Designing evolutionary-based interception strategies to block the transition from precursor phases to multiple myeloma
.
Clin Cancer Res
.
2021
;
27
(
1
):
15
-
23
.
18.
Oben
B
,
Froyen
G
,
Maclachlan
KH
, et al
.
Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities
.
Nat Commun
.
2021
;
12
(
1
):
1861
.
19.
Therneau
TM
,
Kyle
RA
,
Melton
LJ
, et al
.
Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition
.
Mayo Clin Proc
.
2012
;
87
(
11
):
1071
-
1079
.
20.
Pang
L
,
Rajkumar
SV
,
Kapoor
P
, et al
.
Prognosis of young patients with monoclonal gammopathy of undetermined significance (MGUS)
.
Blood Cancer J
.
2021
;
11
(
2
):
26
.
21.
Samur
MK
,
Roncador
M
,
Aktas Samur
A
, et al
.
High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma
.
Blood
.
2023
;
141
(
14
):
1724
-
1736
.
22.
Wang
S
,
Tao
Z
,
Wu
T
,
Liu
XS
.
Sigflow: an automated and comprehensive pipeline for cancer genome mutational signature analysis
.
Bioinformatics
.
2021
;
37
(
11
):
1590
-
1592
.
23.
Baker
TM
,
Lai
S
,
Lynch
AR
, et al
.
The history of chromosomal instability in genome doubled tumors
.
Cancer Discov
.
2023
;
14
(
10
):
1810
-
1822
.
24.
Mitchell
TJ
,
Turajlic
S
,
Rowan
A
, et al
.
Timing the landmark events in the evolution of clear cell renal cell cancer: TRACERx Renal
.
Cell
.
2018
;
173
(
3
):
611
-
623.e17e17
.
You do not currently have access to this content.
Sign in via your Institution